MARKET

MIRA

MIRA

Mira Pharma
NASDAQ
1.200
+0.070
+6.19%
After Hours: 1.220 +0.02 +1.67% 17:17 02/06 EST
OPEN
1.170
PREV CLOSE
1.130
HIGH
1.230
LOW
1.146
VOLUME
102.77K
TURNOVER
--
52 WEEK HIGH
2.450
52 WEEK LOW
0.7300
MARKET CAP
50.25M
P/E (TTM)
-0.7895
1D
5D
1M
3M
1Y
5Y
1D
Mira Pharmaceuticals stellt Pipeline für neuartige orale Therapien bei neurologischen und psychiatrischen Erkrankungen vor
Reuters · 1d ago
Mira Pharmaceuticals Unveils Pipeline Focused on Oral Therapies for Neurologic and Metabolic Disorders
Reuters · 1d ago
Psychedelic: Analyst initiates Definium, Helus with Buy ratings
TipRanks · 2d ago
Mira Pharmaceuticals initiates final cohort of Ketamir-2 Phase 1 study
TipRanks · 5d ago
MIRA Pharmaceuticals Initiated Dosing In Final Cohort of Its Phase 1 Multiple Ascending Dose Trial Of Ketamir-2; The Company Expects to Complete the Phase 1 Clinical Program by the End of Q1 of 2026
Benzinga · 5d ago
Mira Pharmaceuticals startet finale Phase-1-Studie mit Ketamir-2 gegen Chemotherapie-bedingte Neuropathie
Reuters · 5d ago
Mira Pharmaceuticals Begins Final Phase 1 Trial Cohort for Oral Ketamir-2 in Neuropathic Pain
Reuters · 5d ago
MIRA Pharmaceuticals Advances Ketamir-2 Phase 1 to Final Cohort
TipRanks · 5d ago
More
About MIRA
MIRA Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The Company's pipeline includes oral drug candidates designed to address significant unmet medical needs in neuropathic pain, inflammatory pain, obesity, addiction, anxiety, and cognitive decline. It holds exclusive license rights in the United States, Canada and Mexico for Ketamir-2 and MIRA-55, two novel drug candidates designed to address unmet medical needs in neuropathic and inflammatory pain, as well as neuropsychiatric and neurocognitive disorders. Its pipeline also includes SKNY-1, a next-generation oral therapy candidate for obesity and smoking cessation. Ketamir-2 is a patent-pending oral ketamine analog evaluated for the treatment of diabetic neuropathy and is in an ongoing Phase I clinical trial.

Webull offers Mira Pharmaceuticals Inc stock information, including NASDAQ: MIRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MIRA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MIRA stock methods without spending real money on the virtual paper trading platform.